Recurrent NAFLD post-LT: Sisyphus’ boulder or Proteus’ parable?

Odenwald, Matthew A.; Rinella, Mary E.

doi:10.1097/lvt.0000000000000161

Cited by 1 publication

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, statin use improves survival, suggesting that careful attention to metabolic parameters is of utmost importance in this population, where metabolic risk factors typically worsen after LT 65 . Finally, one recent, single arm study reported that the dual peroxisome proliferator activated receptor (PPAR)‐α/γ agonist Saroglitizar reduces hepatic steatosis and improves metabolic parameters post‐LT 67,68 . This study lays important groundwork for future trials modifying both hepatic and cardiometabolic risks of recurrence post‐LT.…”

Section: Recurrence Of the Primary Liver Diseasementioning

confidence: 80%

“…62 However, a recent study found that patients transplanted for MASH at ≥65 years-old or those with diabetes have worse survival than their counterparts, 65 and similar to the non-LT population, 66 cardio-vascular events were common causes of mortality. 62,65 Importantly, statin use improves survival, suggesting that careful attention to metabolic parameters is of utmost importance in this population, where metabolic risk factors typically worsen after LT. 65 Finally, one recent, single arm study reported that the dual peroxisome proliferator activated receptor (PPAR)-α/γ agonist Saroglitizar reduces hepatic steatosis and improves metabolic parameters post-LT. 67,68 This study lays important groundwork for future trials modifying both hepatic and cardiometabolic risks of recurrence post-LT.…”

Section: Metabolic Dysfunction-associated Steatohepatitis (Mash)mentioning

confidence: 94%

See 1 more Smart Citation

Evolving challenges with long‐term care of liver transplant recipients

Odenwald,

Roth,

Reticker

et al. 2023

Clinical Transplantation

Self Cite

View full text Add to dashboard Cite

The number of liver transplants (LT) performed worldwide continues to rise, and LT recipients are living longer post‐transplant. This has led to an increasing number of LT recipients requiring lifelong care. Optimal care post‐LT requires careful attention to both the allograft and systemic issues that are more common after organ transplantation. Common causes of allograft dysfunction include rejection, biliary complications, and primary disease recurrence. While immunosuppression prevents rejection and reduces incidences of some primary disease recurrence, it has detrimental systemic effects. Most commonly, these include increased incidences of metabolic syndrome, various malignancies, and infections. Therefore, it is of utmost importance to optimize immunosuppression regimens to prevent allograft dysfunction while also decreasing the risk of systemic complications. Institutional protocols to screen for systemic disease and heightened clinical suspicion also play an important role in providing optimal long‐term post‐LT care. In this review, we discuss these common complications of LT as well as unique considerations when caring for LT recipients in the years after transplant.

show abstract

Section: Recurrence Of the Primary Liver Diseasementioning

confidence: 80%